Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

被引：18
|
作者：
Abou-Alfa, Ghassan K.
Mollon, Patrick
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Kelley, Robin Kate
Baron, Ari David
Benzaghou, Fawzi
Valcheva, Velichka Valerieva
Hazra, Saswati
Mangeshkar, Milan
Freemantle, Nicholas
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] IPSEN, Abingdon, Oxon, England
[3] UCL, Canc Inst, London, England
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[8] Pacific Hem Onc Assoc, Mill Valley, CA USA
[9] IPSEN, Paris, France
[10] Ipsen Pharma SAS, Paris, France
[11] Prometheus Lab Inc, San Diego, CA USA
[12] Exelixis Inc, San Francisco, CA USA
[13] UCL, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
207
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 241 - 241
  • [2] Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial
    Venerito, Marino
    Abou-Alfa, G. K.
    Mollon, P.
    Meyer, T.
    Cheng, A. -L
    El-Khoueiry, A. B.
    Kelley, R. K.
    Baron, A. D.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 61 - 61
  • [3] Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Strasser, S.
    Abou-Alfa, G.
    Mollon, P.
    Meyer, T.
    Cheng, A.
    El-Khoueiry, A.
    Kelley, R.
    Baron, A.
    Benzaghou, F.
    Valcheva, V.
    Hazra, S.
    Mangeshkar, M.
    Freemantle, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 43 - 43
  • [4] Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Freemantle, Nick
    Mollon, Patrick
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Kelley, Robin K.
    Baron, Ari D.
    Benzaghou, Fawzi
    Mangeshkar, Milan
    Abou-Alfa, Ghassan K.
    EUROPEAN JOURNAL OF CANCER, 2022, 168 : 91 - 98
  • [5] Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    Cicin, Irfan
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Milwee, Steven
    Dubey, Sarita
    Kelley, Robin Kate
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Health-related quality of life in patients with hepatocellular carcinoma: Usefulness of the assessment based on quality-adjusted life years
    Nakayama, N
    Mochida, S
    Akamatsu, M
    Omata, M
    Kudo, M
    Kumada, H
    Sata, M
    Kokudo, N
    Monden, M
    Kanamatsu, T
    Tanaka, K
    Moriwaki, H
    Fujiwara, K
    HEPATOLOGY, 2005, 42 (04) : 390A - 391A
  • [7] Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
    Trojan, J.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    Cicin, I.
    Bolondi, L.
    Kluempen, H. J.
    Chan, S. L.
    Dadduzio, V.
    Milwee, S.
    Dubey, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 243 - 243
  • [8] Association of Adverse Events (AES) with Efficiacy Outcomes for Cabozantinib (C) in Patients (PTS) with Advanced Hepatocellular Carcinoma (AHCC) in the Phase 3 Celestial Trial
    Waidmann, Oliver
    Abou-Alfa, G. K.
    Meker, T.
    Cheng, A. L.
    Cicin, I.
    Bolondi, L.
    Klumpem, H. J.
    Chan, S. L.
    Dadduzio, V.
    Milwee, S.
    Dubey, S.
    Kelley, R. K.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [9] Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y.
    Merle, P.
    Park, J-W.
    Blanc, J-F.
    Lim, H. Y.
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30 : 257 - U138
  • [10] Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Parnis, F.
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Blanc, J. F.
    Lim, H-Y
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 180 - 181
12345